Free Trial
ASX:IHL

Incannex Healthcare (IHL) Stock Price, News & Analysis

Incannex Healthcare logo

About Incannex Healthcare Stock (ASX:IHL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
627,285 shs
Average Volume
N/A
Market Capitalization
$65.07 million
P/E Ratio
N/A
Dividend Yield
16.80%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Incannex Healthcare Limited, a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Docklands, Australia.

Receive IHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incannex Healthcare and its competitors with MarketBeat's FREE daily newsletter.

IHL Stock News Headlines

Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
Incannex reports Q2 EPS (33c) vs (33c) last year
Incannex appoints Alison Wimms to IHL-42X OSA Clinical Advisory Board
Incannex announces results from PK study of IHL-42X
Incannex files to sell 61.39M shares of common stock for holders
See More Headlines

IHL Stock Analysis - Frequently Asked Questions

Incannex Healthcare Limited (ASX:IHL) released its quarterly earnings data on Wednesday, February, 27th. The company reported $0.00 EPS for the quarter. Incannex Healthcare had a negative net margin of 1,129.38% and a negative trailing twelve-month return on equity of 6.81%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Incannex Healthcare investors own include Tahoe Resources (TAHO), Pharmaxis (PXS), Metalicity (MCT), ECN Capital (ECN), 88 Energy (88E) and Hertz Global (HTZ).

Company Calendar

Last Earnings
2/27/2019
Today
4/29/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
ASX:IHL
CIK
N/A
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-19,980,000.00
Net Margins
-1,129.38%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.01 million
Price / Cash Flow
7.14
Book Value
A$0.05 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,590,000,000
Free Float
N/A
Market Cap
$65.07 million
Optionable
Not Optionable
Beta
2.09
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (ASX:IHL) was last updated on 4/29/2025 by MarketBeat.com Staff
From Our Partners